Mutations in isocitrate dehydrogenase (IDH) enzymes are found in 5–15% of patients with AML and inhibitors to both IDH1 (ivosidenib) and IDH2 (enasidenib) mutant enzymes have been approved by the FDA for treatment of relapsed and refractory AML patients. This evidence concerns the gene IDH1 and acute myeloid leukemia.